Florida Society of Clinical Oncology (FLASCO) & Asociacion de Hematologia y Oncologia Medica de PR (AHOMPR)

**UPDATES ON TOPICS IN ONCOLOGY, CANCER CARE DISPARITIES & CURRENT ONCOLOGY PRACTICE ISSUES**

13th ANNUAL PUERTO RICO ONCOLOGY SYMPOSIUM
ORGANIZING COMMITTEE

- Gerardo Colon-Otero, MD
- Robert A. Winn, MD
- Julie Dutil, PhD
- Jose Davila, MD
- Jaime Matta, PhD
- William Caceres, MD, FACP
- Alexis Cruz, MD, FACP
- Katherine Tossas, PhD
- Bhavesh Shah, RPh, BCOP
- Sharee Umpierre, MD
- BC Davis
- Julie Newberry
Gerald Robbins, M.D.- FLASCO Past-President
Dorothy Green, Julie Newberry, BC Davis
FLASCO
• September 25, 2010: First conference
• 2012: Causes of differences in Medicare reimbursement in PR - Dr. Juan Schaening
• Application and selection of AHOMPR as an ASCO State Society - Dr. Jose Davila
• 2013-2024: Ted Okon participation and COA support and participation
• 2014-2024: Updates from PR training programs. Drs. Maribel Tirado and William Caceres
• 2015: First ever participation of ASCO and ASH Presidents in a conference in PR
CONFERENCE ACCOMPLISHMENTS

• 2017: Collaboration of FLASCO, COA, AHOMPR during Hurricane Maria
• 2018-19: FLASCO support of UPR medical students’ Mayo Summer Research Scholarships
• 2019-24: Focus on cancer care disparities
• 2022: Discussion of racism and colorism
• 2022-24: Research poster presentations
• 2024: Supreme court decision on Affirmative Action
Multiple contributors
In Memoriam

Luis Baez Diaz, MD, was a giant in the field of oncology, particularly in Puerto Rico, where he founded the Puerto Rico Minority Underserved NCI Community Oncology Research Program (PRNCORP). Today, because of his efforts, over 18 communities on the island have access to cutting-edge cancer clinical trials sponsored by the National Cancer Institute (NCI).

Dr. Baez Diaz was a leader in the conduct of NCI research, building the PRNCORP to have strong leadership as it continues to be a substantial contributor of minority Hispanic patients to clinical trials. For example, while Principal Investigator of Adult Clinical Trials, he facilitated participation in several landmark trials, such as TAILORx and E1199, both breast cancer treatment studies, and the NCI-MATCH precision medicine trial. He pioneered the development of Spanish translations of clinical trial materials for Spanish-speaking participants in NCI-funded trials—an effort that continues today.
Unrestricted grant support and exhibitors

• **Premier Support**: Astra Zeneca and Gilead

• **Exhibitors**: Amgen, Astellas, AVEO Oncology, BeiGene, Biocartis, Blueprint Medicines, BTG Pharmaceuticals, Eisai, Exact Sciences, Exelixis, Fennec Pharmaceuticals, Genmab, Immunogen, InCyte, IPSEN Biopharmaceuticals, Karyopharm, MorphoSys, Novartis, Pfizer Oncology, Pharmacyclics, Regeneron, Sanofi, Seagen, Servier Oncology, Sobi, SpringWorks therapeutics, Taketa Oncology, Verify PHarmaceuticals